Cosmo Pharmaceuticals

Update in progress

C43.F (Frankfurt)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - General

Cosmo Pharmaceuticals N.V. is a Dublin-based life sciences company that develops and manufactures medicines and offers contract services for gastroenterology, dermatology, and health tech worldwide. Its portfolio includes GI Genius, an AI-assisted real-time endoscopy system for detecting colorectal lesions; and approved therapies such as Winlevi, Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Eleview, Lumeblue, Aemcolo, and Clascoterone (in phase 3 for baldness). It also advances UC, bile acid diarrhea, and oncology programs.

Company score

Sentiment: 0.42; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.19; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.25; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive